Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.92 USD
-0.02 (-2.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $0.90 -0.02 (-2.17%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Aptose Biosciences, Inc. [APTO]
Reports for Purchase
Showing records 41 - 60 ( 144 total )
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
First ''806 Clinical Look Certainly Points in Right Direction
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Results; Encouraging Evolving Data Ahead of Important ASH Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Results; ASH Getting Closer; Target Lowered to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Looks Like Another Window Into CG-806''s Bright Future
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results; Get Clear on CG-806 Thesis Now Ahead of ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
''806 and ''253 Profiles Continue to Strengthen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
New Ball Game as CG-806 IND Goes Active; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Young, Hip, and Reversible: New BTK Drugs on the Block
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Our Critical Investment Points on CG-806 and AACR 2019 Preview
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2018 Results; Engines Ready to Rev in Major Transition Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Anticipation Continues to Grow as CG-806 IND Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We Can''t Wait for CG-806 to Hit the Clinic; Views from KOL Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CG-806 Profile Continues to Impress; Clean Tox and Streamlining Efforts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aptose Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
A New Chapter Begins for APTO-253; Looking Forward to Initial Response Data in Intractable Population; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J